biostudies-literaturePatterson CGNational Institute of Neurological Disorders and StrokeNICHD NIH HHSNCATS NIH HHSNIDDK NIH HHSNINDS NIH HHS855https://www.ebi.ac.uk/biostudies/studies/S-EPMC9535216biostudies-literatureUnknown23(1)<h4>Background</h4>To date, no medication has slowed the progression of Parkinson's disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exercising at high intensity, in terms of slowing disease progression, beyond the well-documented benefit of endurance training on a treadmill for fitness, gait, and functional mobility. This study will determine the efficacy of high-intensity endurance exercise as first-line therapy for persons diagnosed with PD within 3 years, and untreated with symptomatic therapy at baseline.<h4>Methods</h4>This is a multicenter, randomized, evaluator-blinded study of endurance exercise training. The exerTrialsStudy in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.PMC9535216P30 DK048520U24 NS095871U01 NS113851UL1 TR001422P2C HD086844Milton HTansey MGWu LLuthra NChristou DDSpigle WRasmussen BBKang UJGoelz LSPARX3-PSG InvestigatorsJohannsen NMTilley BHondzinski JMHinkle DALamotte GDeik AFWeltman AHurt CPHorak FBCopeland BJAlmeida QJLapierre SMacKinnon CDFessenden AGonzalez-Latapi PLandis CEspay AJStegemoller ELGarland KForoud TOlivier GNSchultz BNelles KPatterson CGBalfany KKohrt WMConroy CSuttman EMarchbank JAmundsen-Huffmaster SChahine LPoon CAlberts JLSchwarzschild MAMarek KNemet TJones KHackney MEDunlap MKBloemer AKidwell AEarhart GMGriffith GRao AKMiller LPanchal NJoslin EJosbeno DLungu CKilbane CFactor SARidgel ALVaillancourt DEEdwards DRamirez-Zamora AChristiansen CLNordahl TJShih LCEllis TDMcKee KESimuni TDalrymple WAMotl RBranson CStevenson MTHaus JMAfshari MNocera JRDale MLSaint-Hilaire MCamicioli RRawson KSFantuzzi GDrummond PMcFarland NRChapman SGil ABMancini MNaito AMelanson ECorcos DMTanner CMRynders CDibble LELarson DSpahn JfalseStudy in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.<h4>Background</h4>To date, no medication has slowed the progression of Parkinson's disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exercising at high intensity, in terms of slowing disease progression, beyond the well-documented benefit of endurance training on a treadmill for fitness, gait, and functional mobility. This study will determine the efficacy of high-intensity endurance exercise as first-line therapy for persons diagnosed with PD within 3 years, and untreated with symptomatic therapy at baseline.<h4>Methods</h4>This is a multicenter, randomized, evaluator-blinded study of endurance exercise training. The exer2022-01-01T00:00:00Z2022 Oct2025-04-22T21:53:06.91Z2025-02-19T01:28:17.124ZS-EPMC95352163620321410.1186/s13063-022-06703-0